-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$50.2574.78% Upside
Spyre Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Spyre Therapeutics, Inc.?
Spyre Therapeutics, Inc. has been rated by research analysts at Stifel Nicolaus, Robert W. Baird, Wells Fargo, BTIG in the past 90 days.